Tempo Therapeutics Raises $19M to Revolutionize Tissue Engineering and Vaccine Innovation with MAP Technology

Tempo Therapeutics, headquartered in San Diego, California, is excited to announce the successful closing of a $19,000,000 funding round that will accelerate our pioneering efforts in the tissue engineering biotechnology field. As industry leaders leveraging our proprietary MAP material science technology, we are revolutionizing the way medicine approaches tissue and organ repair, as well as vaccine development. Our innovative MAP technology enables us to build functional tissue and organs within patients in real time, offering transformative treatment options for a variety of diseases. In parallel, we are developing next-generation vaccine technologies that are both shelf stable and stockpile-able, designed to protect against multiple diseases with a single injection—an advancement that could reshape public health responses around the globe. The funds raised will be strategically deployed to expand our research and development capabilities, enhance our manufacturing processes, and accelerate the translation of our breakthrough technologies from research labs to clinical settings. This infusion of capital is a testament to the confidence that investors have in our mission to harness MAP material technology to empower the future of medicine. It will also enable us to explore new therapeutic areas, forge strategic partnerships, and attract top-tier talent to further solidify our position at the forefront of tissue engineering innovation. With this support, Tempo Therapeutics is poised not only to make significant strides in treating complex diseases but also to redefine the landscape of modern healthcare, positioning us as a key driver in the evolution of next-generation medical interventions.